<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8" />
    <title>Optic Neuritis in Multiple Sclerosis - 50 Slides</title>

    <!-- Reveal.js Core CSS -->
    <link
      rel="stylesheet"
      href="https://cdn.jsdelivr.net/npm/reveal.js@4.5.0/dist/reveal.css"
    />
    <!-- Reveal.js Theme: WHITE (light background, dark text) -->
    <link
      rel="stylesheet"
      href="https://cdn.jsdelivr.net/npm/reveal.js@4.5.0/dist/theme/white.css"
      id="theme"
    />

    <!-- Optional Google Font: Open Sans -->
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Open+Sans&display=swap"
    />

    <style>
      /* Base font styling */
      body,
      .reveal {
        font-family: "Open Sans", sans-serif;
        color: #333;
        background-color: #fff;
      }

      /* Subtle default heading style */
      h2 {
        color: #2c3e50;
        margin-bottom: 0.5em;
        font-weight: 600;
      }

      /* Bullet lists */
      ul,
      ol {
        font-size: 1em;
        line-height: 1.4em;
        margin-left: 1.2em;
        color: #333;
      }

      /* Remove custom overflow so Reveal.js can handle scaling */
      .reveal .slides section {
        position: relative; /* Keep for the eye icon pseudo-element */
        /* Overflow and max-height removed */
      }

      /* Section name in a smaller subheader style */
      .section-name {
        font-size: 0.9em;
        color: #666;
        margin-bottom: 0.3em;
        font-weight: 600;
        text-transform: uppercase;
      }

      /* Eye icon placed via ::after pseudo-element on each slide */
      section.ophthal-slide::after {
        content: "";
        position: absolute;
        top: 10px;
        right: 10px;
        width: 60px;
        height: 30px;
        background: no-repeat center/contain
          url("data:image/svg+xml;utf8,<svg%20width%3D%2250%22%20height%3D%2230%22%20xmlns%3D%22http://www.w3.org/2000/svg%22%20fill%3D%22none%22%20stroke%3D%22%23ccc%22%20stroke-width%3D%222%22><path%20d%3D%22M2%2015%20Q%2025%202%2C%2048%2015%20Q%2025%2028%2C%202%2015Z%22%2F><circle%20cx%3D%2225%22%20cy%3D%2215%22%20r%3D%225%22%20fill%3D%22%23ccc%22%2F><%2Fsvg>");
        opacity: 0.1; /* faint icon */
        pointer-events: none; /* so it doesn’t interfere with clicks */
      }

      /* Title slide styling */
      section.title-slide {
        text-align: center;
        background-color: #f7f7f7;
        color: #2c3e50;
        position: relative;
      }
      section.title-slide::after {
        /* Add the eye icon to the title slide as well */
        content: "";
        position: absolute;
        top: 10px;
        right: 10px;
        width: 60px;
        height: 30px;
        background: no-repeat center/contain
          url("data:image/svg+xml;utf8,<svg%20width%3D%2250%22%20height%3D%2230%22%20xmlns%3D%22http://www.w3.org/2000/svg%22%20fill%3D%22none%22%20stroke%3D%22%23ccc%22%20stroke-width%3D%222%22><path%20d%3D%22M2%2015%20Q%2025%202%2C%2048%2015%20Q%2025%2028%2C%202%2015Z%22%2F><circle%20cx%3D%2225%22%20cy%3D%2215%22%20r%3D%225%22%20fill%3D%22%23ccc%22%2F><%2Fsvg>");
        opacity: 0.1;
        pointer-events: none;
      }
    </style>
  </head>
  <body>
    <div class="reveal">
      <div class="slides">
        <!-- ====== TITLE SLIDE ====== -->
        <section class="title-slide">
          <h2>Optic Neuritis in Multiple Sclerosis</h2>
          <h3>
            A Comprehensive Review (History, Exam, Diagnosis &amp; Management)
          </h3>
          <p>Presented by: Sanaa</p>
          <p>MediVision Eye Care Centre</p>
        </section>

        <!-- ====== SLIDE 2: Outline ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Overview</p>
          <h2>Outline</h2>
          <ol>
            <li>Introduction</li>
            <li>Epidemiology &amp; Risk Factors</li>
            <li>Pathophysiology</li>
            <li>Types of Optic Neuritis</li>
            <li>Relationship Between ON &amp; MS</li>
            <li>Clinical Features</li>
            <li>History Taking</li>
            <li>Clinical Examination</li>
            <li>Investigations</li>
            <li>Differential Diagnosis</li>
            <li>Management</li>
            <li>Prognosis &amp; Follow-Up</li>
            <li>Special Considerations &amp; Future Directions</li>
            <li>Conclusion</li>
            <li>References</li>
          </ol>
        </section>

        <!-- ====== SLIDE 3: Introduction ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 1: Introduction</p>
          <h2>Definition of Optic Neuritis</h2>
          <ul>
            <li>
              <strong>Optic Neuritis (ON):</strong> Inflammatory demyelination
              of the optic nerve
            </li>
            <li>
              <strong>Presentation:</strong> Subacute onset of unilateral vision
              loss, eye pain
            </li>
            <li>
              <strong>Significance:</strong> Often the first manifestation of MS
            </li>
          </ul>
        </section>

        <!-- ====== SLIDE 4: Introduction ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 1: Introduction</p>
          <h2>Importance of Studying ON in MS</h2>
          <ul>
            <li>
              ON is often the <strong>first demyelinating event</strong> in MS
            </li>
            <li>~15–20% of MS patients initially present with ON</li>
            <li>
              Insight into <strong>autoimmune demyelination</strong> in the CNS
            </li>
            <li>Early detection can prompt disease-modifying therapies</li>
          </ul>
        </section>

        <!-- ====== SLIDE 5: Epidemiology ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 2: Epidemiology &amp; Risk Factors</p>
          <h2>Epidemiology</h2>
          <ul>
            <li><strong>Age:</strong> Typically 20–40 years</li>
            <li><strong>Gender:</strong> Female predominance (~3:1)</li>
            <li>
              <strong>Geographic Variation:</strong> Higher incidence farther
              from the equator
            </li>
            <li>
              <strong>Association:</strong> 50% of isolated ON develop MS within
              15 years
            </li>
          </ul>
        </section>

        <!-- ====== SLIDE 6: Risk Factors ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 2: Epidemiology &amp; Risk Factors</p>
          <h2>Risk Factors</h2>
          <ul>
            <li>
              <strong>Genetic Predisposition:</strong> Certain HLA genotypes
            </li>
            <li>
              <strong>Environmental:</strong> Low Vitamin D, smoking, possible
              viral triggers (EBV)
            </li>
            <li><strong>Autoimmune Disorders:</strong> May predispose to ON</li>
          </ul>
        </section>

        <!-- ====== SLIDE 7: Pathophysiology ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 3: Pathophysiology</p>
          <h2>Basic Immunopathology</h2>
          <ul>
            <li>
              <strong>Autoimmune Attack:</strong> T-cells, B-cells, and
              antibodies target myelin
            </li>
            <li>
              <strong>Key Cells:</strong> CD4+, CD8+ T cells, B cells,
              macrophages
            </li>
            <li>
              <strong>Inflammatory Cascade:</strong> Cytokines (IL-2, IFN-γ)
              promote demyelination, axonal injury
            </li>
          </ul>
        </section>

        <!-- ====== SLIDE 8 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 3: Pathophysiology</p>
          <h2>Demyelination in the Optic Nerve</h2>
          <ul>
            <li><strong>Myelin Loss:</strong> Slows nerve conduction</li>
            <li>
              <strong>Axonal Injury:</strong> Potentially permanent if severe
            </li>
            <li>
              <strong>Remyelination:</strong> Explains partial or full visual
              recovery
            </li>
          </ul>
        </section>

        <!-- ====== SLIDE 9 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 3: Pathophysiology</p>
          <h2>Role of MS Plaques</h2>
          <ul>
            <li><strong>MS Plaques:</strong> Focal CNS demyelination</li>
            <li>
              <strong>Locations:</strong> Periventricular, juxtacortical,
              infratentorial, spinal cord
            </li>
            <li>
              <strong>MRI:</strong> T2/FLAIR lesions; active lesions enhance
              with gadolinium
            </li>
            <li>
              <strong>Optic Nerve Lesions:</strong> Enhancement indicates acute
              inflammation
            </li>
          </ul>
        </section>

        <!-- ====== SLIDE 10 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 4: Types of Optic Neuritis</p>
          <h2>Typical vs. Atypical ON</h2>
          <ul>
            <li>
              <strong>Typical (Demyelinating) ON:</strong>
              <ul>
                <li>Associated with MS</li>
                <li>Usually unilateral, painful, good recovery</li>
                <li>MRI often shows MS-type lesions</li>
              </ul>
            </li>
            <li>
              <strong>Atypical ON:</strong>
              <ul>
                <li>Causes: NMO, MOG, infections, sarcoidosis</li>
                <li>Often bilateral or severe; may have worse prognosis</li>
              </ul>
            </li>
          </ul>
        </section>

        <!-- ====== SLIDE 11 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 4: Types of Optic Neuritis</p>
          <h2>Clinical Clues to Atypical ON</h2>
          <ul>
            <li>Poor steroid response</li>
            <li>Recurrent bilateral involvement</li>
            <li>Severe vision loss at onset</li>
            <li>Systemic symptoms (rash, arthralgias)</li>
            <li>Marked disc swelling on imaging</li>
          </ul>
        </section>

        <!-- ====== SLIDE 12 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">
            Section 5: Relationship Between ON &amp; MS
          </p>
          <h2>ON as an Early Indicator of MS</h2>
          <ul>
            <li>15–20% of MS patients present with ON initially</li>
            <li>~50% develop MS within 15 years after first ON</li>
            <li>MRI brain lesions greatly increase MS conversion risk</li>
          </ul>
        </section>

        <!-- ====== SLIDE 13 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">
            Section 5: Relationship Between ON &amp; MS
          </p>
          <h2>MS Diagnostic Criteria (Brief)</h2>
          <ul>
            <li>
              <strong>McDonald Criteria:</strong> Dissemination in time &amp;
              space
            </li>
            <li>
              <strong>Clinical Attacks + MRI Evidence:</strong>
              <ul>
                <li>≥2 CNS regions (space)</li>
                <li>Lesions at different times (time)</li>
              </ul>
            </li>
            <li>ON can fulfill part of the clinical requirement</li>
          </ul>
        </section>

        <!-- ====== SLIDE 14 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 6: Clinical Features</p>
          <h2>Vision Loss</h2>
          <ul>
            <li><strong>Nature:</strong> Sudden/subacute (~days to 1 week)</li>
            <li><strong>Severity:</strong> Mild blurring to complete loss</li>
            <li>
              <strong>Laterality:</strong> Typically unilateral in demyelinating
              ON
            </li>
            <li>
              <strong>Progression:</strong> Worsens ~1 week, then
              stabilizes/improves
            </li>
          </ul>
        </section>

        <!-- ====== SLIDE 15 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 6: Clinical Features</p>
          <h2>Pain with Eye Movement</h2>
          <ul>
            <li>~90% report retro-orbital pain</li>
            <li>Pain worsens with movement</li>
            <li>Linked to inflammation of optic nerve sheath</li>
          </ul>
        </section>

        <!-- ====== SLIDE 16 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 6: Clinical Features</p>
          <h2>Color Vision Defects</h2>
          <ul>
            <li>Red desaturation is classic</li>
            <li>Ishihara plates often detect color discrimination issues</li>
            <li>Residual color deficits may persist after acuity recovers</li>
          </ul>
        </section>

        <!-- ====== SLIDE 17 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 6: Clinical Features</p>
          <h2>Visual Field Defects</h2>
          <ul>
            <li>Central or cecocentral scotoma common</li>
            <li>Diffuse or altitudinal deficits are less frequent</li>
            <li>Confrontation (screen), automated perimetry (detailed)</li>
          </ul>
        </section>

        <!-- ====== SLIDE 18 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 6: Clinical Features</p>
          <h2>Uhthoff’s Phenomenon</h2>
          <ul>
            <li>Temporary worsening of symptoms with heat/exercise</li>
            <li>
              Raised temperature impairs conduction in demyelinated fibers
            </li>
            <li>Can transiently reduce visual acuity</li>
          </ul>
        </section>

        <!-- ====== SLIDE 19 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 6: Clinical Features</p>
          <h2>Relative Afferent Pupillary Defect (RAPD)</h2>
          <ul>
            <li>Detected by swinging flashlight test</li>
            <li>Indicates unilateral/asymmetric optic nerve dysfunction</li>
            <li>More pronounced RAPD = more severe ON</li>
          </ul>
        </section>

        <!-- ====== SLIDE 20 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 7: History Taking</p>
          <h2>Key Points (Part 1)</h2>
          <ul>
            <li>Chief complaint: onset &amp; nature of vision loss</li>
            <li>Pain: especially with eye movement</li>
            <li>Timeline: duration, progression</li>
            <li>Possible triggers: infection, vaccination, stress</li>
          </ul>
        </section>

        <!-- ====== SLIDE 21 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 7: History Taking</p>
          <h2>Key Points (Part 2)</h2>
          <ul>
            <li>
              <strong>Systemic Review:</strong>
              <ul>
                <li>Neurological: numbness, weakness, ataxia</li>
                <li>Urinary changes, diplopia</li>
              </ul>
            </li>
            <li>
              <strong>Past Medical History:</strong>
              <ul>
                <li>Prior ON episodes</li>
                <li>Autoimmune/neuro disorders</li>
              </ul>
            </li>
            <li>
              <strong>Family History:</strong> MS or other autoimmune diseases
            </li>
          </ul>
        </section>

        <!-- ====== SLIDE 22 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 7: History Taking</p>
          <h2>Additional History Details</h2>
          <ul>
            <li>Medication use: steroids, immunomodulators</li>
            <li>Social history: smoking, alcohol, occupation</li>
            <li>Travel history: potential infections</li>
            <li>Red flags: fever, weight loss, etc.</li>
          </ul>
        </section>

        <!-- ====== SLIDE 23 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 8: Clinical Examination</p>
          <h2>Visual Acuity Testing</h2>
          <ul>
            <li>Check best-corrected VA (Snellen, ETDRS)</li>
            <li>Compare with contralateral eye</li>
            <li>Note any pinhole improvement</li>
          </ul>
        </section>

        <!-- ====== SLIDE 24 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 8: Clinical Examination</p>
          <h2>Pupillary Examination</h2>
          <ul>
            <li>Size, shape, symmetry</li>
            <li>Direct &amp; consensual light reflex</li>
            <li>Swinging flashlight test (RAPD)</li>
            <li>Near response (accommodation, convergence)</li>
          </ul>
        </section>

        <!-- ====== SLIDE 25 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 8: Clinical Examination</p>
          <h2>Color Vision Testing</h2>
          <ul>
            <li>Ishihara plates for color discrimination</li>
            <li>Red desaturation test for subtle deficits</li>
            <li>Document severity &amp; changes over time</li>
          </ul>
        </section>

        <!-- ====== SLIDE 26 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 8: Clinical Examination</p>
          <h2>Visual Field Evaluation</h2>
          <ul>
            <li>Confrontation testing (screen)</li>
            <li>Automated perimetry (Humphrey) for detail</li>
            <li>Identify scotomas or generalized field loss</li>
          </ul>
        </section>

        <!-- ====== SLIDE 27 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 8: Clinical Examination</p>
          <h2>Fundoscopic Examination</h2>
          <ul>
            <li>Retrobulbar neuritis: normal disc in acute ON</li>
            <li>Possible disc swelling (papillitis)</li>
            <li>Chronic disc pallor = optic atrophy</li>
          </ul>
        </section>

        <!-- ====== SLIDE 28 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 8: Clinical Examination</p>
          <h2>Neurological Examination</h2>
          <ul>
            <li>Cranial nerves: EOM (III, IV, VI), trigeminal (V), etc.</li>
            <li>Motor: weakness, spasticity</li>
            <li>Sensory: pinprick, proprioception</li>
            <li>Coordination/gait: check for ataxia, spastic gait</li>
          </ul>
        </section>

        <!-- ====== SLIDE 29 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 9: Investigations</p>
          <h2>MRI of the Brain &amp; Orbits (1)</h2>
          <ul>
            <li>
              <strong>Purpose:</strong> Identify CNS demyelinating lesions
            </li>
            <li>
              <strong>Optic Nerve Enhancement:</strong> T1 + gadolinium → active
              inflammation
            </li>
            <li>
              <strong>T2/FLAIR:</strong> Hyperintensities showing older/new
              plaques
            </li>
          </ul>
        </section>

        <!-- ====== SLIDE 30 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 9: Investigations</p>
          <h2>MRI of the Brain &amp; Orbits (2)</h2>
          <ul>
            <li>
              <strong>High MS Risk:</strong> Multiple lesions, especially
              periventricular
            </li>
            <li>
              <strong>Optic Nerve Findings:</strong> Enhancement, swelling in
              acute ON
            </li>
          </ul>
        </section>

        <!-- ====== SLIDE 31 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 9: Investigations</p>
          <h2>Visual Evoked Potentials (VEP)</h2>
          <ul>
            <li>Measures conduction latency from retina to occipital cortex</li>
            <li>Prolonged P100 = demyelination</li>
            <li>Helps detect subclinical lesions, supports MS diagnosis</li>
          </ul>
        </section>

        <!-- ====== SLIDE 32 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 9: Investigations</p>
          <h2>Optical Coherence Tomography (OCT)</h2>
          <ul>
            <li>Cross-sectional imaging of retinal nerve fiber layer (RNFL)</li>
            <li>Thinning indicates axonal loss post-ON</li>
            <li>Monitors disease progression or treatment response</li>
          </ul>
        </section>

        <!-- ====== SLIDE 33 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 9: Investigations</p>
          <h2>Additional Laboratory Tests</h2>
          <ul>
            <li><strong>Serologic:</strong> NMO-IgG (AQP4), MOG-IgG</li>
            <li>
              <strong>Basic Labs:</strong> CBC, ESR, CRP, ANA (exclude other
              causes)
            </li>
            <li><strong>CSF:</strong> Oligoclonal bands supportive of MS</li>
          </ul>
        </section>

        <!-- ====== SLIDE 34 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 10: Differential Diagnosis</p>
          <h2>Major Differentials</h2>
          <ul>
            <li>Neuromyelitis Optica (NMO)</li>
            <li>MOG Antibody Disease</li>
            <li>Ischemic Optic Neuropathy</li>
            <li>Leber’s Hereditary Optic Neuropathy</li>
            <li>Infectious ON (e.g., syphilis, Lyme)</li>
            <li>Sarcoid/Autoimmune Optic Neuritis</li>
          </ul>
        </section>

        <!-- ====== SLIDE 35 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 10: Differential Diagnosis</p>
          <h2>Clues to Different Etiologies</h2>
          <ul>
            <li>
              <strong>NMO:</strong> Severe, bilateral, spinal cord lesions
            </li>
            <li><strong>MOG-ON:</strong> Disc swelling, often good recovery</li>
            <li>
              <strong>Ischemic ON:</strong> Painless, altitudinal defect, older
              patients
            </li>
            <li>
              <strong>Leber’s:</strong> Gradual bilateral central loss, maternal
              inheritance
            </li>
            <li>
              <strong>Infectious:</strong> Systemic signs, positive serologies
            </li>
          </ul>
        </section>

        <!-- ====== SLIDE 36 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 11: Management</p>
          <h2>General Approach</h2>
          <ul>
            <li>Confirm diagnosis: clinical + MRI ± VEP</li>
            <li>Assess MS risk: Brain MRI for lesions</li>
            <li>Exclude atypical (NMO, MOG) if suspicion</li>
          </ul>
        </section>

        <!-- ====== SLIDE 37 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 11: Management</p>
          <h2>High-Dose Corticosteroids</h2>
          <ul>
            <li>First-line: IV methylprednisolone 1 g/day x 3–5 days</li>
            <li>Oral steroids may follow or be used if mild</li>
            <li>Speeds recovery but may not alter final VA outcome</li>
          </ul>
        </section>

        <!-- ====== SLIDE 38 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 11: Management</p>
          <h2>Disease-Modifying Therapies (DMTs)</h2>
          <ul>
            <li>Indicated if MS or high risk of MS</li>
            <li>
              Examples:
              <ul>
                <li>Interferon β, Glatiramer, Dimethyl fumarate</li>
                <li>Natalizumab, Ocrelizumab, etc.</li>
              </ul>
            </li>
            <li>Reduce relapse rate &amp; slow progression</li>
          </ul>
        </section>

        <!-- ====== SLIDE 39 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 11: Management</p>
          <h2>Other Immunomodulatory Therapies</h2>
          <ul>
            <li>
              <strong>NMO:</strong> Steroids, plasmapheresis, rituximab for
              maintenance
            </li>
            <li>
              <strong>MOG-ON:</strong> Steroids ± IVIG or immunosuppressants
            </li>
            <li>Target underlying autoimmune mechanisms</li>
          </ul>
        </section>

        <!-- ====== SLIDE 40 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 11: Management</p>
          <h2>Plasma Exchange (Plasmapheresis)</h2>
          <ul>
            <li>Used for steroid-refractory acute ON</li>
            <li>Removes autoantibodies/immune complexes</li>
            <li>May improve vision in otherwise refractory ON</li>
          </ul>
        </section>

        <!-- ====== SLIDE 41 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 11: Management</p>
          <h2>Symptomatic Management</h2>
          <ul>
            <li>Pain control: NSAIDs, acetaminophen</li>
            <li>Vision aids: large print, contrast enhancements</li>
            <li>Cooling strategies to reduce Uhthoff’s phenomenon</li>
          </ul>
        </section>

        <!-- ====== SLIDE 42 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 12: Prognosis &amp; Follow-Up</p>
          <h2>Natural Course of ON</h2>
          <ul>
            <li>Partial recovery often starts 2–4 weeks post-onset</li>
            <li>Many have good final VA in typical ON</li>
            <li>Color/contrast deficits may persist</li>
          </ul>
        </section>

        <!-- ====== SLIDE 43 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 12: Prognosis &amp; Follow-Up</p>
          <h2>Risk of Progression to MS</h2>
          <ul>
            <li>High lesion load on MRI → greater risk</li>
            <li>
              Close monitoring with repeat neuro exams &amp; MRI if new symptoms
            </li>
            <li>Early DMT can delay or reduce MS progression</li>
          </ul>
        </section>

        <!-- ====== SLIDE 44 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 12: Prognosis &amp; Follow-Up</p>
          <h2>Optic Neuritis Treatment Trial (ONTT)</h2>
          <ul>
            <li>Landmark trial: steroids vs. placebo in acute ON</li>
            <li>
              IV steroids hastened recovery but no major long-term VA difference
            </li>
            <li>Oral steroids alone had higher short-term recurrence</li>
            <li>MRI lesions predicted higher MS risk</li>
          </ul>
        </section>

        <!-- ====== SLIDE 45 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 13: Special Considerations</p>
          <h2>Pediatric Optic Neuritis</h2>
          <ul>
            <li>Often bilateral in children</li>
            <li>May follow viral infection or vaccination</li>
            <li>High-dose steroids; evaluate for demyelinating disease</li>
          </ul>
        </section>

        <!-- ====== SLIDE 46 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 13: Special Considerations</p>
          <h2>Pregnancy &amp; ON/MS</h2>
          <ul>
            <li>
              MS relapses may decrease during pregnancy, rebound postpartum
            </li>
            <li>Some DMTs contraindicated; therapy must be adjusted</li>
            <li>Short-term IV steroids are generally safe if needed</li>
          </ul>
        </section>

        <!-- ====== SLIDE 47 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 13: Future Directions</p>
          <h2>Emerging Therapies</h2>
          <ul>
            <li>Neuroprotective agents to preserve axons</li>
            <li>Remyelinating therapies to enhance repair</li>
            <li>
              Biologics: advanced monoclonal antibodies targeting key immune
              pathways
            </li>
          </ul>
        </section>

        <!-- ====== SLIDE 48 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 13: Special Considerations</p>
          <h2>Patient Education &amp; Support</h2>
          <ul>
            <li>Explain ON–MS link &amp; typical disease course</li>
            <li>Lifestyle: avoid smoking, optimize Vitamin D, manage stress</li>
            <li>Resources: MS societies, vision rehab, counseling</li>
          </ul>
        </section>

        <!-- ====== SLIDE 49 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 14: Conclusion</p>
          <h2>Key Takeaways</h2>
          <ul>
            <li>ON: unilateral vision loss, eye pain, color desaturation</li>
            <li>Often the first sign of MS (50% risk over ~15 years)</li>
            <li>Diagnose via clinical exam, MRI, VEP</li>
            <li>Treat with high-dose IV steroids, consider DMT for MS risk</li>
            <li>Generally favorable visual recovery in typical ON</li>
          </ul>
        </section>

        <!-- ====== SLIDE 50 ====== -->
        <section class="ophthal-slide">
          <p class="section-name">Section 15: References</p>
          <h2>References</h2>
          <ul>
            <li>
              WebMD:
              <a
                href="https://www.webmd.com/multiple-sclerosis/optic-neuritis-ms-vision"
                target="_blank"
              >
                Optic Neuritis in MS
              </a>
            </li>
            <li>
              PubMed:
              <a
                href="https://pubmed.ncbi.nlm.nih.gov/12789593/"
                target="_blank"
              >
                Optic Neuritis &amp; MS (PMID 12789593)
              </a>
            </li>
            <li>Optic Neuritis Treatment Trial (ONTT) Publications</li>
            <li>National Multiple Sclerosis Society</li>
            <li>UpToDate: Optic Neuritis – Diagnosis &amp; Management</li>
          </ul>
          <p><strong>Thank You!</strong></p>
        </section>
      </div>
    </div>

    <!-- Reveal.js Scripts -->
    <script src="https://cdn.jsdelivr.net/npm/reveal.js@4.5.0/dist/reveal.js"></script>
    <script>
      Reveal.initialize({
        hash: true, // Add a URL hash to link directly to slides
        slideNumber: true, // Show slide numbers
        controls: true, // Show navigation controls
        progress: true, // Show progress bar
        center: true, // Center slides vertically
        transition: "slide", // Slide transition
        // No explicit width/height => Reveal will auto-scale the slides
      });
    </script>
  </body>
</html>
